3/18
02:00 am
ipsey
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
Low
Report
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
3/12
02:30 am
ipsey
Ipsen appoints Michelle C. Werner as EVP, President of North America
Low
Report
Ipsen appoints Michelle C. Werner as EVP, President of North America
2/17
02:05 pm
ipsey
IPSEN (OTCMKTS:IPSEY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Neutral
Report
IPSEN (OTCMKTS:IPSEY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
2/12
02:23 pm
ipsey
Ipsen SA (IPSEY) Full Year 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ... [Yahoo! Finance]
Neutral
Report
Ipsen SA (IPSEY) Full Year 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ... [Yahoo! Finance]
2/12
01:00 am
ipsey
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
Neutral
Report
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
1/30
12:00 pm
ipsey
Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
Neutral
Report
Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
1/29
01:00 am
ipsey
Ipsen nominates Peter Guenter to its Board of Directors
Neutral
Report
Ipsen nominates Peter Guenter to its Board of Directors
1/27
01:00 am
ipsey
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team
Low
Report
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team
1/21
11:45 am
ipsey
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
Neutral
Report
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
1/13
12:19 pm
ipsey
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
Neutral
Report
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
1/8
05:02 am
ipsey
IPSEN (OTCMKTS:IPSEY) was downgraded by analysts at UBS Group AG to a "neutral" rating.
Neutral
Report
IPSEN (OTCMKTS:IPSEY) was downgraded by analysts at UBS Group AG to a "neutral" rating.